Michael Ulz

Stock Analyst at Baird

(2.19)
# 1180
Out of 5,441 analysts
167
Total ratings
Success rate
Average return
45 Stocks
Name Action PT Current % Upside Ratings Updated
KPTI Karyopharm Therapeut...
Maintains: Outperform
42 25
3.73 570.24% 7 Aug 12, 2025
ALNY Alnylam Pharmaceutic...
Maintains: Equal-Weight
312 405
434.89 -6.87% 11 Aug 1, 2025
IONS Ionis Pharmaceutical...
Upgrades: Overweight
55 62
40.84 51.81% 5 Jul 31, 2025
SLN Silence Therapeutics
Maintains: Overweight
45 25
5.09 391.16% 12 May 9, 2025
VKTX Viking Therapeutics
Maintains: Overweight
105 102
38.19 167.09% 3 Apr 24, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
40 20
3.08 549.35% 2 Apr 1, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
30 22
1.32 1566.67% 6 Apr 1, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
29
11.09 161.5% 1 Mar 10, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Underweight
11 7
8.52 -17.84% 7 Mar 5, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
24 20
1.97 915.23% 4 Feb 28, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Equal-Weight
20 5
5.38 -7.06% 5 Feb 12, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
18 10
0.97 930.93% 2 Feb 3, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
46 96
48.32 98.68% 4 Jan 28, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
48 52
11.23 363.05% 2 Aug 14, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
110 115
129.46 -11.17% 9 Jul 12, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
53 57
65.86 -13.45% 3 Jun 18, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
36 27
17.2 56.98% 4 May 13, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Equal-Weight
47 65
64.97 0.05% 4 Apr 11, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
3 7
0.94 644.68% 8 Feb 27, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Underweight
23 12
9.81 17.23% 4 Jan 5, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
15 27
9.19 193.8% 2 Aug 16, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
42 37
58.7 -36.97% 9 Aug 9, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Equal-Weight
35 40
39.95 0.13% 4 May 1, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
30 20
1.51 1224.5% 3 Mar 24, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
45
2.93 1435.84% 1 Feb 1, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
20 10
0.68 1370.59% 3 Jan 27, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
6 8
n/a n/a 5 Jan 27, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Equal-Weight
3
2.75 9.09% 1 Jan 27, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Equal-Weight
18 30
4.28 600.93% 1 Jan 27, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
135 90
116.3 -22.61% 3 Aug 4, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
15 7
1.88 272.34% 3 May 11, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
25 30
1.28 2243.75% 3 Mar 30, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Equal-Weight
n/a
n/a n/a 1 Feb 1, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
84 36
1.4 2471.43% 2 Jan 5, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
45
10.11 345.1% 1 Oct 8, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
500
3.49 14226.65% 1 Sep 23, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
300 500
5.98 8261.2% 2 May 28, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
30
n/a n/a 1 Apr 16, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
3 1
n/a n/a 4 Mar 29, 2019
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
7 4
15.14 -73.58% 3 Oct 22, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
17 0
n/a n/a 2 Sep 21, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
680 544
n/a n/a 2 Jun 13, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
85 80
27.39 192.08% 2 Nov 3, 2017
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
12 15
6.66 125.23% 3 Jul 12, 2017
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
127 182
74.96 142.8% 2 Feb 27, 2017